Previous close | 2.1300 |
Open | 1.9500 |
Bid | 0.6500 |
Ask | 3.5000 |
Strike | 25.00 |
Expiry date | 2024-10-18 |
Day's range | 1.9500 - 2.1300 |
Contract range | N/A |
Volume | |
Open interest | 2.5k |
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally ad
Key Insights iTeos Therapeutics will host its Annual General Meeting on 11th of June Salary of US$578.9k is part of CEO...
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy- GSK to provide update on GALAXIES program at upcoming investor event in June- RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close- Pro forma ca